Merck/Ridgeback’s Lagevrio Could Get Another Chance As Others Face Limitations
New Analysis Shows No COVID-19 At Days 3 Or 5
New data for molnupiravir could mean new commercial life for Merck and Ridgeback’s oral COVID-19 therapy, which had fallen behind due to the outstanding efficacy for Pfizer’s Paxlovid.
You may also be interested in...
David Peacock, President, Asia Pacific, MSD tells Scrip how Lagevrio has gained dominance in certain parts of the world, though Paxlovid may have received the ‘lion’s share’ of public attention.
Group’s final report said evidence was inadequate to demonstrate a net health benefit versus symptomatic care for Lagevrio, a drug that has already taken a back seat to Pfizer’s Paxlovid.
The constantly mutating SARS-CoV-2 has evaded yet another antibody therapy, but Vir and GSK hope that a higher dose of Xevudy could retain some efficacy against BA.2.